| LABT 0.5887 207.58% | SOXL 44.15 -33.79% | BDMD 0.1573 44.18% | NVDA 181.985 -9.07% | TQQQ 51.09 -17.91% | INTC 53.99 -7.35% | SPDN 8.8415 4.26% | NTCL 0.3108 -18.17% | SPCX 124.73 -8.23% | SOXS 78.29 34.20% | KORU 6.8497 -34.33% | NVD 5.45 18.22% | QQQ 650.55 -5.98% | GRAB 3.4799 3.57% | PLCE 0.3257 35.15% | SQQQ 49.045 18.01% | IREN 18.6187 -14.24% | SPY 734.545 -4.21% | TSLG 4.0501 -21.66% | RWM 14.8 4.67% | ZNB 1.0912 75.43% | NOK 7.5128 -9.05% | WULF 10.265 -12.26% | PLUG 1.355 -7.19% | MUU 13.235 -31.18% | JDZG 0.3945 30.80% | NU 11.605 -3.21% | CRWV 44.07 -8.98% | DVLT 0.058 -15.94% | CIFR 5.74 -11.69% | TSLL 8.1005 -21.89% | SHFS 0.0265 -16.67% | SOFI 16.08 -7.48% | AMZN 258.92 -2.67% | TSLA 343.335 -10.87% | MU 671.295 -15.58% | SNAP 5.125 -13.43% | IBIT 43.035 -5.06% | KWEB 24.705 1.58% | EEM 58.205 -5.54% | HYG 77.295 -0.29% | CDT 0.0442 -13.16% | RIG 5.13 -5.87% | ONDS 4.585 -13.00% | AMD 412.9 -15.52% | SMCI 27.21 -8.07% | PLTD 5.669 10.08% | KEEL 1.7 -19.05% | XLE 62.075 -2.27% | SOXX 133.455 -11.11%

This pancreatic cancer treatment is on track for ‘one of the best drug launches of all time'

Revolution Medicines' brand-new treatment brought in far higher sales than expected in its first few weeks on the market.

TC Trade Conquest Newsroom November 5, 2026 ·1 min read

This pancreatic cancer treatment is on track for ‘one of the best drug launches of all time'

Key takeaways

Revolution Medicines' brand-new treatment brought in far higher sales than expected in its first few weeks on the market.
Reported by MarketWatch. Open the full story for every detail.
Published November 5, 2026.

Revolution Medicines' brand-new treatment brought in far higher sales than expected in its first few weeks on the market.

Read the full story at marketwatch.com ↗

Want trade ideas like this in real time? Subscribe to Trade Conquest.

More news